Literature DB >> 29358460

Prevalence of Cardiovascular Disease and Its Risk Factors in Primary Aldosteronism: A Multicenter Study in Japan.

Youichi Ohno1, Masakatsu Sone2, Nobuya Inagaki1, Toshinari Yamasaki1, Osamu Ogawa1, Yoshiyu Takeda1, Isao Kurihara1, Hiroshi Itoh1, Hironobu Umakoshi1, Mika Tsuiki1, Takamasa Ichijo1, Takuyuki Katabami1, Yasushi Tanaka1, Norio Wada1, Yui Shibayama1, Takanobu Yoshimoto1, Yoshihiro Ogawa1, Junji Kawashima1, Katsutoshi Takahashi1, Megumi Fujita1, Minemori Watanabe1, Yuichi Matsuda1, Hiroki Kobayashi1, Hirotaka Shibata1, Kohei Kamemura1, Michio Otsuki1, Yuichi Fujii1, Koichi Yamamoto1, Atsushi Ogo1, Shintaro Okamura1, Shozo Miyauchi1, Tomikazu Fukuoka1, Shoichiro Izawa1, Takashi Yoneda1, Shigeatsu Hashimoto1, Toshihiko Yanase1, Tomoko Suzuki1, Takashi Kawamura1, Yasuharu Tabara1, Fumihiko Matsuda1, Mitsuhide Naruse1.   

Abstract

There have been several clinical studies examining the factors associated with cardiovascular disease (CVD) in patients with primary aldosteronism (PA); however, their results have left it unclear whether CVD is affected by the plasma aldosterone concentration or hypokalemia. We assessed the PA database established by the multicenter JPAS (Japan Primary Aldosteronism Study) and compared the prevalence of CVD among patients with PA with that among age-, sex-, and blood pressure-matched essential hypertension patients and participants with hypertension in a general population cohort. We also performed binary logistic regression analysis to determine which parameters significantly increased the odds ratio for CVD. Of the 2582 patients with PA studied, the prevalence of CVD, including stroke (cerebral infarction, cerebral hemorrhage, or subarachnoid hemorrhage), ischemic heart disease (myocardial infarction or angina pectoris), and heart failure, was 9.4% (stroke, 7.4%; ischemic heart disease, 2.1%; and heart failure, 0.6%). The prevalence of CVD, especially stroke, was higher among the patients with PA than those with essential hypertension/hypertension. Hypokalemia (K+ ≤3.5 mEq/L) and the unilateral subtype significantly increased adjusted odds ratios for CVD. Although aldosterone levels were not linearly related to the adjusted odds ratio for CVD, patients with plasma aldosterone concentrations ≥125 pg/mL had significantly higher adjusted odds ratios for CVD than those with plasma aldosterone concentrations <125 pg/mL. Thus, patients with PA seem to be at a higher risk of developing CVD than patients with essential hypertension. Moreover, patients with PA presenting with hypokalemia, the unilateral subtype, or plasma aldosterone concentration ≥125 pg/mL are at a greater risk of CVD and have a greater need for PA-specific treatments than others.
© 2018 American Heart Association, Inc.

Entities:  

Keywords:  aldosterone; cardiovascular diseases; hyperaldosteronism; myocardial ischemia; stroke

Mesh:

Substances:

Year:  2018        PMID: 29358460     DOI: 10.1161/HYPERTENSIONAHA.117.10263

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  41 in total

Review 1.  [Primary aldosteronism : Genetics and pathology].

Authors:  U Scholl
Journal:  Pathologe       Date:  2019-12       Impact factor: 1.011

2.  Adrenal Tissue-Specific Deletion of TASK Channels Causes Aldosterone-Driven Angiotensin II-Independent Hypertension.

Authors:  Nick A Guagliardo; Junlan Yao; Eric J Stipes; Sylvia Cechova; Thu H Le; Douglas A Bayliss; David T Breault; Paula Q Barrett
Journal:  Hypertension       Date:  2019-02       Impact factor: 10.190

3.  In situ metabolomics of aldosterone-producing adenomas.

Authors:  Masanori Murakami; Yara Rhayem; Thomas Kunzke; Na Sun; Annette Feuchtinger; Philippe Ludwig; Tim Matthias Strom; Celso Gomez-Sanchez; Thomas Knösel; Thomas Kirchner; Tracy Ann Williams; Martin Reincke; Axel Karl Walch; Felix Beuschlein
Journal:  JCI Insight       Date:  2019-09-05

4.  MicroRNA-21 ablation exacerbates aldosterone-mediated cardiac injury, remodeling, and dysfunction.

Authors:  Maryam Syed; Jana P Ball; Keisa W Mathis; Michael E Hall; Michael J Ryan; Marc E Rothenberg; Licy L Yanes Cardozo; Damian G Romero
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-08-28       Impact factor: 4.310

5.  Higher risk of chronic kidney disease and progressive kidney function impairment in primary aldosteronism than in essential hypertension. Case-control study.

Authors:  María Fernández-Argüeso; Eider Pascual-Corrales; Nuria Bengoa Rojano; Ana García Cano; Lucía Jiménez Mendiguchía; Marta Araujo-Castro
Journal:  Endocrine       Date:  2021-04-02       Impact factor: 3.633

Review 6.  [Update on endocrine hypertension].

Authors:  B Lechner; D Heinrich; S Nölting; A Osswald-Kopp; G Rubinstein; J Sauerbeck; F Beuschlein; M Reincke
Journal:  Internist (Berl)       Date:  2018-11       Impact factor: 0.743

7.  Diagnosis of primary aldosteronism in the hypertension specialist centers in Italy: a national survey.

Authors:  Giacomo Pucci; Silvia Monticone; Claudia Agabiti Rosei; Giulia Balbi; Fabio Bertacchini; Fabio Ragazzo; Francesca Saladini; Martino F Pengo
Journal:  J Hum Hypertens       Date:  2018-08-06       Impact factor: 3.012

8.  Aldosterone-induced microRNAs act as feedback regulators of mineralocorticoid receptor signaling in kidney epithelia.

Authors:  Nejla Ozbaki-Yagan; Xiaoning Liu; Andrew J Bodnar; Jacqueline Ho; Michael Bruce Butterworth
Journal:  FASEB J       Date:  2020-07-11       Impact factor: 5.191

9.  Serum-soluble (pro)renin receptor concentration as a biomarker for organ damage in primary aldosteronism.

Authors:  Kaoru Yamashita; Satoshi Morimoto; Yasufumi Seki; Daisuke Watanabe; Atsuhiro Ichihara
Journal:  Hypertens Res       Date:  2019-08-13       Impact factor: 3.872

10.  Adrenal artery ablation for primary aldosteronism without apparent aldosteronoma: An efficacy and safety, proof-of-principle trial.

Authors:  Hexuan Zhang; Qiang Li; Xiaoli Liu; Zhigang Zhao; Hongbo He; Fang Sun; Yangning Hong; Xunmei Zhou; Yingsha Li; Rufei Shen; Xiaona Bu; Zhencheng Yan; Hongting Zheng; Gangyi Yang; Zhiming Zhu
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-08-27       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.